Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Antimicrobial Agents|March 9, 2023
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspectsSimon E Koele, Patrick P J Phillips, Caryn M Upton, et al.
Clinical Pharmacokinetics|June 6, 2022
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with BedaquilineLénaïg Tanneau, Mats O Karlsson, Andreas H Diacon, et al.
Open Forum Infectious Diseases|October 9, 2025
Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysisAndrea Llamas-Lopez, James A Seddon, Felicia C Chow, et al.
Clinical Pharmacology and Therapeutics|June 10, 2022
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing RegimensLénaïg Tanneau, Mats O Karlsson, Susan L Rosenkranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
Clinical Pharmacokinetics|October 11, 2025
Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive TherapySaskia Janssen, Thanakorn Vongjarudech, Mats O Karlsson, et al.
Eclinicalmedicine|May 18, 2022
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trialCaryn M Upton, Rob C van Wijk, Laurynas Mockeliunas, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical TrialVeronique De Jager, Nikhil Gupte, Silvia Nunes, et al.
Nature Medicine|February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trialAndreas H Diacon, Clifton E Barry, Alex Carlton, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
Pageof 3